AP NEWS

Polyarticular Juvenile Idiopathic Arthritis (PJIA): 2018 Pipeline Review, H1 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 9 and 2 respectively.

Companies Mentioned

Biocon Ltd Coherus BioSciences Inc Fresenius SE & Co KGaA Genor BioPharma Co Ltd Livzon Pharmaceutical Group Inc Momenta Pharmaceuticals Inc Mycenax Biotech Inc Oncobiologics Inc Oncodesign SA Regeneron Pharmaceuticals Inc Sandoz International GmbH UCB SA

Key Topics Covered

Introduction Report Coverage Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drug Profiles Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/76vg3v/polyarticular?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005963/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 01:49 PM/DISC: 06/11/2018 01:49 PM

http://www.businesswire.com/news/home/20180611005963/en

AP RADIO
Update hourly